Antibiotic_JJ Susceptibilities_NNS of_IN Parachlamydia_NP acanthamoeba_NN in_IN Amoebae_NP Parachlamydia_NP acanthamoeba_NNS are_VBP intracellular_JJ bacteria_NNS of_IN amoebae_NNS and_CC are_VBP considered_VBN potential_JJ etiological_JJ agents_NNS of_IN human_JJ pneumonia_NN ._SENT We_PP have_VBP determined_VBN the_DT in_IN vitro_NP antibiotic_JJ susceptibilities_NNS of_IN two_CD strains_NNS (_( strain_NN Bn9_NP and_CC Hall_NP 's_POS coccus_NN )_) in_IN Acanthamoeba_NP polyphaga_NP ._SENT The_DT two_CD strains_NNS were_VBD susceptible_JJ to_TO tetracyclines_NNS ,_, macrolides_NNS ,_, and_CC rifampin_NN ,_, but_CC resistant_JJ to_TO fluoroquinolones_NNS ._SENT Based_VBN on_IN 16S_JJ ribosomal_JJ DNA_NN sequence_NN comparison_NN ,_, the_DT taxonomic_JJ classification_NN of_IN species_NNS belonging_VBG to_TO the_DT order_NN Chlamydiales_NP has_VBZ been_VBN recently_RB reassessed_VBN ,_, and_CC a_DT new_JJ family_NN ,_, Parachlamydiaceae_NP ,_, has_VBZ been_VBN proposed_VBN ._SENT This_DT family_NN now_RB comprises_VBZ two_CD genera_NNS :_: i.e._FW ,_, the_DT genus_NN Parachlamydia_NP with_IN Parachlamydia_NP acanthamoeba_NN as_IN a_DT type_NN species_NN ,_, and_CC the_DT genus_NN Neochlamydia_NP with_IN Neochlamydia_NP hartmannellae_NNS as_IN the_DT type_NN species_NN ._SENT Strains_NNS belonging_VBG to_TO the_DT species_NNS P._NP acanthamoeba_NNS include_VBP the_DT type_NN strain_NN Bn9_NP (_( ATCC_NP VR_NP 1476_CD )_) ,_, isolate_NN Berg17_NP ,_, Hall_NP 's_POS coccus_NN ,_, and_CC unnamed_JJ isolates_NNS (_( ,_, R._NP J._NP Birtles_NP ,_, T._NP J._NP Rowbotham_NP ,_, C._NP Storey_NP ,_, T._NP J._NP Marrie_NP ,_, and_CC D._NP Raoult_NP ,_, Letter_NP ,_, Lancet_NP 349:925-926_CD ,_, 1997_CD )_) ,_, which_WDT are_VBP all_RB strictly_RB intracellular_JJ bacteria_NNS with_IN variable_JJ Gram_NP staining_VBG properties_NNS and_CC which_WDT display_VBP more_JJR than_IN 99_CD %_NN 16S_JJ rRNA_NN gene_NN similarity_NN (_( Birtles_NP et_FW al._FW ,_, Letter_NP )_) ._SENT Parachlamydia_NP spp._NP naturally_RB infect_VB Acanthamoeba_NP ._SENT Trophozoites_NNS of_IN Acanthamoeba_NP hosting_VBG chlamydia-like_JJ bacteria_NNS have_VBP been_VBN isolated_VBN in_IN patients_NNS with_IN fever_NN associated_VBN with_IN use_NN of_IN humidifiers_NNS in_IN Vermont_NP (_( i.e._FW ,_, Hall_NP 's_POS coccus_NN )_) and_CC from_IN human_JJ nasal_JJ mucosa_NN (_( i.e._FW ,_, the_DT Bn9_NP and_CC Berg17_JJ strains_NNS )_) ._SENT Moreover_RB ,_, fourfold_RB rising_VBG titers_NNS of_IN antibodies_NNS directed_VBN against_IN Hall_NP 's_POS coccus_NN have_VBP been_VBN detected_VBN by_IN an_DT immunofluorescence_NN technique_NN in_IN sera_NN from_IN patients_NNS suffering_VBG from_IN pneumonia_NN of_IN undefined_JJ cause_NN in_IN Ohio_NP and_CC Nova_NP Scotia_NP ,_, Canada_NP (_( Birtles_NP et_FW al._FW ,_, Letter_NP )_) ._SENT These_DT sera_NN did_VBD not_RB react_VB with_IN Chlamydia_NP trachomatis_NN ,_, Chlamydophila_NP pneumoniae_NNS ,_, or_CC Chlamydophila_NP psittaci_NP antigens_NNS (_( Birtles_NP et_FW al._FW ,_, Letter_NP )_) ._SENT More_RBR recently_RB ,_, Marrie_NP et_FW al._FW reported_JJ detection_NN of_IN anti-P_NN ._SENT acanthamoeba_NN antibodies_NNS (_( antibody_NN titer_NN of_IN 179_CD [_SYM there]phi_RB [_SYM there]sigma_NP 121:50_CD )_) in_IN 8_CD of_IN 376_CD patients_NNS (_( similar2_JJ %_NN )_) with_IN community-acquired_JJ pneumonia_NN compared_VBN with_IN 0_CD of_IN 511_CD healthy_JJ controls_NNS ._SENT Thus_RB ,_, a_DT recent_JJ medical_JJ interest_NN in_IN Parachlamydia_NP strains_NNS has_VBZ arisen_VBN because_IN of_IN the_DT potential_JJ etiological_JJ role_NN in_IN community-acquired_JJ pneumonia_NN as_RB well_RB as_IN nosocomial_JJ pneumonia_NN ,_, especially_RB in_IN patients_NNS with_IN a_DT humidifier_NN ._SENT In_IN this_DT respect_NN ,_, the_DT knowledge_NN of_IN their_PP$ antibiotic_JJ susceptibilities_NNS could_MD be_VB of_IN primary_JJ clinical_JJ importance_NN ._SENT Especially_RB ,_, it_PP is_VBZ of_IN particular_JJ interest_NN to_TO verify_VB that_DT current_JJ first-line_NN recommendations_NNS for_IN antibiotic_JJ therapy_NN of_IN pneumonia_NN apply_VB to_TO this_DT group_NN of_IN pathogens_NNS ._SENT P._NP acanthamoeba_NNS strain_VBP Bn9_NP was_VBD kindly_RB provided_VBN by_IN R._NP Amann_NP (_( Lehrstuhl_NP fur_NN Mikrobiologie_NP ,_, Technische_NP Universitat_NP Munchen_NP ,_, Munich_NP ,_, Germany_NP )_) ,_, whereas_IN Hall_NP 's_POS coccus_NN was_VBD a_DT gift_NN from_IN T._NP J._NP Robotham_NP (_( Public_NP Health_NP Laboratory_NP ,_, Leeds_NP ,_, United_NP Kingdom_NP )_) ._SENT Parachlamydia_NP organisms_NNS were_VBD cultured_VBN in_IN Acanthamoeba_NP polyphaga_NP ,_, grown_VBN in_IN 25-cm2_JJ culture_NN flasks_NNS (_( Becton_NP Dickinson_NP ,_, Le_NP Pont_NP de_NP Claix_NP ,_, France_NP )_) containing_VBG PYG_NP medium_NN until_IN almost_RB complete_JJ lysis_NN of_IN amoebae_NNS (_( i.e._FW ,_, 4_CD days_NNS later_RBR )_) ._SENT Cell_NN supernatants_NNS were_VBD then_RB recovered_VBN and_CC centrifuged_VBN at_IN 1,500_CD rpm_NN (_( 700_CD x_SYM g_NN )_) for_IN 10_CD min_NN to_TO remove_VB cell_NN debris_NN ._SENT A_DT Parachlamydia_NP inoculum_NN was_VBD prepared_VBN for_IN each_DT strain_NN tested_VBN by_IN diluting_VBG supernatants_NNS 1:100_CD in_IN Page_NP 's_POS amoebal_JJ saline_NN ,_, which_WDT corresponded_VBD to_TO approximately_RB 108_CD bacteria/ml_NN ._SENT Titration_NN of_IN Parachlamydia_NP was_VBD obtained_VBN by_IN inoculating_VBG 10-fold_JJ serial_JJ dilutions_NNS of_IN the_DT primary_JJ inoculum_NN to_TO uninfected_JJ amoebal_JJ cultures_NNS and_CC determining_VBG the_DT highest_JJS dilution_NN allowing_VBG lysis_NN of_IN amoebal_JJ monolayers_NNS after_IN 4_CD days_NNS of_IN incubation_NN of_IN cultures_NNS at_IN 30C_JJ ._SENT Uninfected_JJ amoebae_NNS ,_, cultured_VBN in_IN PYG_NP medium_NN ,_, were_VBD harvested_VBN by_IN gentle_JJ shaking_VBG of_IN monolayers_NNS and_CC dispensed_VBN (_( 160_CD mul_NN per_IN well_RB of_IN a_DT 5.105-organism/ml_JJ inoculum_NN )_) in_IN 96-well_NN microtiter_NN plates_NNS (_( D._NP Dutcher_NP ,_, Brumath_NP ,_, France_NP )_) ._SENT Each_DT well_NN received_VBD 20_CD mul_NN of_IN Parachlamydia_NP inoculum_NN (_( i.e._FW ,_, final_JJ inoculum_NN of_IN about_RB 106_CD bacteria/ml_NN )_) ._SENT After_IN a_DT 2-h_JJ incubation_NN of_IN infected_JJ amoebal_JJ cultures_NNS at_IN 30C_JJ ,_, antibiotics_NNS were_VBD added_VBN (_( i.e._FW ,_, 20_CD mul_NN of_IN 10-fold_NN the_DT desired_VBN final_JJ concentrations_NNS )_) ._SENT Controls_NNS were_VBD drug-free_JJ uninfected_JJ amoebae_NNS (_( as_IN amoebal_JJ viability_NN controls_NNS )_) ,_, uninfected_JJ amoebae_NNS with_IN the_DT various_JJ antibiotic_JJ concentrations_NNS tested_VBN (_( as_IN amoebal_JJ antibiotic_JJ toxicity_NN controls_NNS )_) ,_, and_CC drug-free_JJ infected_JJ amoebae_NNS (_( as_IN Parachlamydia_NP growth_NN controls_NNS )_) ._SENT We_PP also_RB verified_VBD that_IN the_DT P._NP acanthamoeba_NN strains_NNS tested_VBN did_VBD not_RB grow_VB in_IN Page_NP 's_POS amoebal_JJ saline_NN in_IN the_DT absence_NN of_IN amoebae_NNS ._SENT Drug-free_JJ controls_NNS received_VBD 20_CD mul_NN of_IN saline_NN instead_RB of_IN the_DT antibiotic_JJ solution_NN ._SENT Cultures_NNS were_VBD incubated_VBN at_IN 30C_JJ and_CC observed_VBD each_DT day_NN under_IN an_DT inverted_JJ microscope_NN at_IN a_DT magnification_NN of_IN x400_NN until_IN complete_JJ lysis_NN of_IN amoebal_JJ monolayers_NNS in_IN Parachlamydia-infected_JJ drug-free_JJ controls_NNS occurred_VBD ._SENT By_IN this_DT simple_JJ technique_NN ,_, MICs_NP corresponded_VBD to_TO the_DT lowest_JJS antibiotic_NN concentration_NN that_WDT prevented_VBD Parachlamydia_NP growth_NN (_( i.e._FW ,_, destruction_NN of_IN amoebal_JJ cultures_NNS after_IN 4_CD days_NNS of_IN incubation_NN )_) ._SENT Escherichia_NP coli_NNS C.I.P._NP 53.126_CD and_CC Staphylococcus_NP aureus_NN C.I.P._NP 103811_CD were_VBD obtained_VBN from_IN the_DT Pasteur_NP Institute_NP (_( Institut_NP Pasteur_NP ,_, Marnes_NP La_NP Coquette_NP ,_, France_NP )_) and_CC were_VBD used_VBN to_TO control_VB the_DT antibiotic_JJ concentrations_NNS tested_VBN ,_, with_IN Mueller-Hinton_NP broth_NN as_IN the_DT antibiotic_JJ assay_NN medium_NN according_VBG to_TO the_DT procedure_NN recommended_VBN by_IN the_DT National_NP Committee_NP for_IN Clinical_NP Laboratory_NP Standards_NPS ._SENT No_DT antibiotic_JJ concentration_NN tested_VBN displayed_VBD a_DT toxic_JJ effect_NN against_IN amoebae_NNS ._SENT MICs_NNS for_IN E._NP coli_NNS C.I.P._NP 53.126_CD and_CC Staphylococcus_NP aureus_NN C.I.P._NP 103811_CD were_VBD compatible_JJ with_IN those_DT determined_VBN by_IN the_DT Pasteur_NP Institute_NP ._SENT P._NP acanthamoeba_NN strains_NNS grew_VBD well_RB in_IN A._NP polyphaga_NP cells_NNS ,_, with_IN complete_JJ lysis_NN of_IN amoebal_JJ monolayers_NNS in_IN drug-free_JJ cultures_NNS after_IN 4_CD days_NNS of_IN incubation_NN at_IN 30C_JJ ._SENT Among_IN the_DT beta-lactams_NNS tested_VBD ,_, penicillin_NN G_NP ,_, amoxicillin_NP ,_, ceftriaxone_NN ,_, and_CC imipenem_NN were_VBD ineffective_JJ at_IN concentrations_NNS up_RB to_TO 32_CD mug/ml_NN ._SENT Both_DT strains_NNS were_VBD susceptible_JJ to_TO aminoglycosides_NNS ,_, macrolides_NNS (_( including_VBG the_DT newer_JJR ketolide_NN ,_, telithromycin_NP )_) ,_, doxycycline_NN ,_, cotrimoxazole_NN ,_, and_CC rifampin_NN ._SENT In_IN contrast_NN ,_, vancomycin_NP ,_, the_DT activity_NN of_IN which_WDT is_VBZ almost_RB restricted_VBN to_TO gram-positive_JJ bacteria_NNS ,_, was_VBD ineffective_JJ ._SENT Thiamphenicol_NP and_CC ,_, more_RBR importantly_RB ,_, the_DT fluoroquinolone_NN compounds_VBZ ofloxacin_NN and_CC ciprofloxacin_NN were_VBD not_RB bacteriostatic_JJ at_IN the_DT concentrations_NNS tested_VBD ._SENT We_PP have_VBP evaluated_VBN in_IN vitro_NN susceptibilities_NNS of_IN two_CD strains_NNS belonging_VBG to_TO the_DT species_NN P._NP acanthamoeba_NN (_( i.e._FW ,_, Bn9_NP and_CC Hall_NP 's_POS coccus_NN )_) ,_, with_IN A._NP polyphaga_NP as_IN an_DT in_IN vitro_NP cell_NN system_NN to_TO support_VB growth_NN of_IN these_DT strictly_RB intracellular_JJ bacteria_NNS ._SENT An_DT amoebal_JJ system_NN was_VBD used_VBN because_IN of_IN the_DT impossibility_NN of_IN growing_VBG these_DT bacteria_NNS in_IN the_DT other_JJ cell_NN systems_NNS we_PP currently_RB use_VBP in_IN our_PP$ laboratory_NN ,_, including_VBG McCoy_NP cells_NNS ,_, Vero_NP cells_NNS ,_, P388D1_JJ macrophage-like_JJ cells_NNS ,_, or_CC human_JJ embryonic_JJ lung_NN fibroblast_NN cells_NNS ._SENT Our_PP$ model_NN was_VBD based_VBN upon_IN inhibition_NN of_IN amoebal_JJ lysis_NN due_JJ to_TO bacterial_JJ multiplication_NN when_WRB antibiotics_NNS were_VBD added_VBN to_TO the_DT culture_NN supernatant_JJ compared_VBN to_TO that_DT of_IN drug-free_JJ controls_NNS ._SENT Thus_RB ,_, it_PP was_VBD critical_JJ to_TO verify_VB that_DT amoebal_JJ lysis_NN was_VBD not_RB related_VBN to_TO antibiotic_JJ toxicity_NN ._SENT Despite_IN these_DT technical_JJ limitations_NNS ,_, our_PP$ model_NN allowed_VBD us_PP for_IN the_DT first_JJ time_NN to_TO define_VB the_DT antibiotic_JJ susceptibility_NN pattern_NN of_IN P._NP acanthamoeba_NN and_CC to_TO compare_VB it_PP with_IN those_DT previously_RB reported_VBN for_IN C._NP trachomatis_NN ,_, Chlamydophila_NP pneumoniae_NNS ,_, and_CC Chlamydophila_NP psittaci_NP ,_, species_NN that_WDT also_RB belong_VBP to_TO the_DT order_NN Chlamydiales_NP ._SENT P._NP acanthamoeba_NP strains_NNS BN9_NP and_CC Hall_NP 's_POS coccus_NN were_VBD found_VBN resistant_JJ to_TO all_DT beta-lactams_NNS tested_VBD ._SENT The_DT in_IN vitro_NN activity_NN of_IN beta-lactams_NNS against_IN C._NP trachomatis_NN ,_, C._NP pneumoniae_NNS ,_, and_CC C._NP psittaci_NP has_VBZ been_VBN demonstrated_VBN ._SENT Although_IN these_DT antibiotics_NNS are_VBP not_RB considered_VBN first-line_NN antibiotic_JJ therapy_NN for_IN Chlamydia-related_JJ pneumonia_NN ,_, amoxicillin_NP has_VBZ been_VBN used_VBN successfully_RB in_IN pregnant_JJ women_NNS with_IN genital_JJ infection_NN due_JJ to_TO C._NP trachomatis_NN ._SENT In_IN contrast_NN ,_, we_PP found_VBD aminoglycosides_NNS to_TO be_VB bacteriostatic_JJ against_IN P._NP acanthamoeba_NN strains_NNS ,_, whereas_IN C._NP trachomatis_NN has_VBZ been_VBN reported_VBN to_TO be_VB highly_RB resistant_JJ to_TO gentamicin_NN ._SENT Cotrimoxazole_NP could_MD inhibit_VB the_DT growth_NN of_IN P._NP acanthamoeba_NN and_CC is_VBZ also_RB effective_JJ against_IN C._NP trachomatis_NN ._SENT In_IN contrast_NN ,_, C._NP pneumoniae_NP and_CC C._NP psittaci_NNS are_VBP resistant_JJ to_TO this_DT antibiotic_JJ combination_NN ._SENT More_RBR surprisingly_RB ,_, P._NP acanthamoeba_NN strains_NNS were_VBD found_VBN to_TO be_VB resistant_JJ to_TO fluoroquinolones_NNS ,_, whereas_IN C._NP trachomatis_NN ,_, C._NP pneumoniae_NNS ,_, and_CC C._NP psittaci_NNS are_VBP highly_RB susceptible_JJ to_TO these_DT drugs_NNS ._SENT DNA_NP gyrase_NN is_VBZ usually_RB the_DT primary_JJ target_NN of_IN fluoroquinolones_NNS in_IN gram-negative_JJ bacteria_NNS ,_, and_CC resistance_NN to_TO fluoroquinolones_NNS due_JJ to_TO mutation_NN in_IN gyrA_NN (_( the_DT gene_NN encoding_VBG the_DT alpha_NN subunit_NN of_IN DNA_NP gyrase_NN )_) has_VBZ been_VBN reported_VBN in_IN C._NP trachomatis_NN ._SENT The_DT possibility_NN of_IN gyrA-mediated_JJ natural_JJ resistance_NN to_TO fluoroquinolones_NNS in_IN P._NP acanthamoeba_NN should_MD be_VB assessed_VBN ._SENT Our_PP$ results_NNS should_MD be_VB specifically_RB examined_VBN considering_VBG the_DT potential_JJ role_NN of_IN Parachlamydia_NP spp._NP as_IN etiological_JJ agents_NNS of_IN human_JJ pneumonia_NN ._SENT beta-Lactams_NNS are_VBP considered_VBN first-line_NN antibiotic_JJ therapy_NN of_IN Streptococcus_NP pneumoniae-related_JJ pneumonia_NN ,_, but_CC are_VBP poorly_RB effective_JJ against_IN intracellular_JJ pathogens_NNS responsible_JJ for_IN atypical_JJ pneumonia_NN ,_, such_JJ as_IN Chlamydia_NP spp._NP ,_, Legionella_NP pneumophila_NP ,_, Mycoplasma_NP pneumoniae_NNS ,_, or_CC Coxiella_NP burnetii_NP ._SENT This_DT may_MD also_RB apply_VB for_IN P._NP acanthamoeba_NP ,_, a_DT species_NN resistant_NN in_IN vitro_NN to_TO these_DT agents_NNS ._SENT In_IN contrast_NN ,_, the_DT susceptibility_NN of_IN P._NP acanthamoeba_NN to_TO macrolides_NNS and_CC tetracycline_NN suggests_VBZ that_IN the_DT current_JJ practice_NN of_IN prescribing_VBG a_DT macrolide_NN or_CC a_DT tetracycline_NN compound_NN in_IN patients_NNS with_IN atypical_JJ pneumonia_NN may_MD well_RB apply_VB in_IN case_NN of_IN Parachlamydia_NP infection_NN ._SENT The_DT new_JJ ketolide_NN compound_NN telithromycin_NN ,_, which_WDT is_VBZ active_JJ against_IN erythromycin-resistant_JJ S._NP pneumoniae_NNS ,_, as_RB well_RB as_IN against_IN the_DT intracellular_JJ pathogens_NNS C._NP pneumoniae_NNS ,_, L._NP pneumophila_NP ,_, M._NP pneumoniae_NNS ,_, and_CC C._NP burnetii_NP ,_, was_VBD found_VBN also_RB active_JJ against_IN the_DT Parachlamydia_NP strains_NNS ._SENT Fluoroquinolones_NP ,_, especially_RB ofloxacin_NN and_CC ciprofloxacin_NN ,_, have_VBP been_VBN advocated_VBN as_IN a_DT possible_JJ alternative_NN to_TO macrolides_NNS in_IN patients_NNS suffering_VBG atypical_JJ pneumonia_NN ,_, although_IN their_PP$ equivalence_NN to_TO erythromycin_NN in_IN case_NN of_IN legionellosis_NN is_VBZ still_RB disputed_VBN ._SENT Interestingly_RB ,_, we_PP found_VBD P._NP acanthamoeba_NN to_TO be_VB highly_RB resistant_JJ to_TO these_DT compounds_NNS in_IN vitro_NN ._SENT TABLE_NN 1_CD |_SYM MICs_NP for_IN Parachlamydia_NP sp_NN ._SENT ,_, including_VBG the_DT Bn9_NP strain_NN and_CC Hall_NP 's_POS coccus_NN ,_, as_RB determined_VBN in_IN an_DT A._NP polyphaga_NN culture_NN model_NN 